References
- CosnesJGower-RousseauCSeksikPCortotAEpidemiology and natural history of inflammatory bowel diseasesGastroenterology201114061785179421530745
- IrvineEJQuality of life of patients with ulcerative colitis: past, present, and futureInflamm Bowel Dis200814455456517973299
- AdamsSMBornemannPHUlcerative colitisAm Fam Physician2013871069970523939448
- KugathasanSJuddRHHoffmannRGEpidemiologic and clinical characteristics of children with newly diagnosed inflammatory bowel disease in Wisconsin: a statewide population-based studyJ Pediatr2003143452553114571234
- KornbluthASacharDBUlcerative colitis practice guidelines in adults: American College of Gastroenterology, Practice Parameters CommitteeAm J Gastroenterol2010105350152320068560
- D’HaensGSandbornWJBarrettKHodgsonIStreckPOnce-daily MMX® mesalamine for endoscopic maintenance of remission of ulcerative colitisAm J Gastroenterol201210771064107722565161
- KaneSKatzSJamalMMStrategies in maintenance for patients receiving long-term therapy (SIMPLE): a study of MMX mesalamine for the long-term maintenance of quiescent ulcerative colitisInflamm Bowel Dis20121861026103321837775
- LichtensteinGRKammMASandbornWJLyneAJosephREMMX mesalazine for the induction of remission of mild-to-moderately active ulcerative colitis: efficacy and tolerability in specific patient subpopulationsAliment Pharmacol Ther200827111094110218363894
- SandbornWJKammMALichtensteinGRLyneAButlerTJosephREMMX Multi Matrix System mesalazine for the induction of remission in patients with mild-to-moderate ulcerative colitis: a combined analysis of two randomized, double-blind, placebo-controlled trialsAliment Pharmacol Ther200726220521517593066
- SutherlandLMacdonaldJKOral 5-aminosalicylic acid for induction of remission in ulcerative colitisCochrane Database Syst Rev20062CD00054316625536
- FordACAchkarJPKhanKJEfficacy of 5-aminosalicylates in ulcerative colitis: systematic review and meta-analysisAm J Gastroenterol2011106460161621407188
- ZeislerBLererTMarkowitzJOutcome following aminosalicylate therapy in children newly diagnosed with ulcerative colitisJ Pediatr Gastroenterol Nutr2013561121822847466
- QuirosJAHeymanMBPohlJFSafety, efficacy, and pharmacokinetics of balsalazide in pediatric patients with mild-to-moderate active ulcerative colitis: results of a randomized, double-blind studyJ Pediatr Gastroenterol Nutr200949557157919633577
- US Department of Health and Human ServicesFood and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Veterinary Medicine (CVM)Guidance for Industry. Bioanalytical Method Validation2001
- LIALDA® (mesalamine) delayed-release tablets, for oral use [package insert]Wayne, PAShire US Inc.2014
- Shire Development IncLialda (mesalamine) delayed release tablets clinical pharmacology biopharmaceutics reviewFood and Drug Administration Web site Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/022000s000TOC.cfmAccessed June 19, 2014
- BealSLSheinerLBBoeckmannABauerRJNONMEM User’s Guides 1989–2009Ellicott City, MD, USAICON Development Solutions2009
- AndersonBJHolfordNHMechanism-based concepts of size and maturity in pharmacokineticsAnnu Rev Pharmacol Toxicol20084830333217914927